Targeting protein myristoylation for the treatment of prostate cancer

Chemotherapeutic agents for the treatment of various stages of prostate cancer have shown promising effects on overall survival of the patient. Emerging in 2004, the taxanes docetaxel and cabazitaxel have become the standard chemotherapeutic approaches. These agents have been explored for treatment of metastatic castration-sensitive or resistant prostate cancer. Docetaxel in combination with androgen deprivation therapy has consistently shown improvement in the overall survival for eligible patients with high-volume or earlier stages of metastatic castration-sensitive prostate cancer. Cabazitaxel has been used mainly for post-docetaxel treatment or following resistance to docetaxel [1]. While the future of chemotherapy treatments will focus on the combination of drugs to mitigate cross-resistance, more options for treatments are urgently needed to improve patient survival rate